These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22820660)

  • 21. Low-grade serous ovarian cancer: A review.
    Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
    Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors.
    Anglesio MS; Arnold JM; George J; Tinker AV; Tothill R; Waddell N; Simms L; Locandro B; Fereday S; Traficante N; Russell P; Sharma R; Birrer MJ; ; deFazio A; Chenevix-Trench G; Bowtell DD
    Mol Cancer Res; 2008 Nov; 6(11):1678-90. PubMed ID: 19010816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
    Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
    Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
    Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
    Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.
    Capper D; Berghoff AS; Magerle M; Ilhan A; Wöhrer A; Hackl M; Pichler J; Pusch S; Meyer J; Habel A; Petzelbauer P; Birner P; von Deimling A; Preusser M
    Acta Neuropathol; 2012 Feb; 123(2):223-33. PubMed ID: 22012135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical Investigation of BRAF p.V600E mutations in thyroid carcinoma using 2 separate BRAF antibodies.
    Fisher KE; Neill SG; Ehsani L; Caltharp SA; Siddiqui MT; Cohen C
    Appl Immunohistochem Mol Morphol; 2014 Sep; 22(8):562-7. PubMed ID: 24897065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
    J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
    Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
    Combe P; Chauvenet L; Lefrère-Belda MA; Blons H; Rousseau C; Oudard S; Pujade-Lauraine E
    Invest New Drugs; 2015 Dec; 33(6):1267-70. PubMed ID: 26490654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
    Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
    Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.
    Verbruggen MB; Sieben NL; Roemen GM; Rockx DA; van Diest PJ; Verheijen RH; Dorsman JC
    Int J Gynecol Cancer; 2009 Dec; 19(9):1560-3. PubMed ID: 19955937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum of
    Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
    Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
    Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
    Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 38. BRAF polymorphisms and the risk of ovarian cancer of low malignant potential.
    Kelemen L; James M; Spurdle A; Campbell I; Chang-Claude J; Peel D; Anton-Culver H; Berchuck A; Schildkraut J; Whittemore A; McGurie V; DiCioccio RA; Duffy D; Chenevix-Trench G
    Gynecol Oncol; 2005 Jun; 97(3):807-12. PubMed ID: 15904951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
    Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
    Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.